Low-concentration atropine eyedrops for myopia control in a multi-racial cohort of Australian children: A randomised clinical trial.
Samantha Sze-Yee LeeGareth LinghamMagdalena BlaszkowskaPaul G SanfilippoAdrian KoayMaria FranchinaAudrey ChiaJames J LoughmanDaniel Ian FlitcroftChristopher J HammondAugusto Azuara-BlancoJulie M CreweAntony ClarkDavid A MackeyPublished in: Clinical & experimental ophthalmology (2022)
In Australian children, 0.01% atropine eyedrops were safe, well-tolerated, and had a modest myopia-control effect, although there was an apparent decrease in efficacy between 18 and 24 months, which is likely driven by a higher dropout rate in the placebo group.